University of Pittsburgh Medical Center Community Medicine Inc. (UPMC CMI) Primary Care Practices
Pittsburgh, Pennsylvania, 15213, United States
NCT Number: NCT01611168
The proposed research study aims to determine whether applying the University of Pittsburgh Medical Center Nurse-Directed Diabetes Management Protocols (NDMPs) leads to improved clinical outcome and process measures as recommended by American Diabetes Association (ADA), quality of life, treatment satisfaction and medication adherence for adults with diabetes, and favorable providers' satisfaction as compared to usual diabetes care. Furthermore, the cost-effectiveness of performing the NDMPs compared to usual diabetes care in primary care settings will also be assessed.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15213, United States
This proposed study is a multi-practice, cluster-design, prospective randomized controlled trial with a total study intervention period of 12 months. This prospective randomized controlled trial will assess the effectiveness of performing NDMPs by the registered nurse supervised by a physician (the intervention group) in comparison with usual diabetes care (the usual care group) for adults with diabetes in primary care settings. The study population will be recruited from University of Pittsburgh Medical Center Community Medicine Inc. (CMI) primary care practices in urban and suburban communities surrounding Pittsburgh, PA. Among these CMI practices, ten practices receive diabetes education services from University of Pittsburgh Diabetes Institute and will be the intervention group. These diabetes education services will be enhanced by the addition of NDMPs intervention. In addition, we will select another 10 CMI practices to be the usual care group. This group receives standard diabetes education with no use of NDMPs. One-hundred and fifty participants will be recruited across practices within each study group (i.e., 300 in total). Outcomes assessed in this study include clinical outcome and process measures as recommended by ADA, participants' quality of life, treatment satisfaction, and medication adherence, and providers' satisfaction, and costs/expenditure. Assessments will be done at baseline, and three and 12 months after the study entry. Analysis of the study outcomes will be based on intention-to-treat to determine (1) within-group differences between the baseline and follow-up visits, and (2) between-group differences between the intervention group and the usual care group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
Time frame: 1 year
Change in HbA1c blood test
Time frame: 1 year
Change in systolic and diastolic blood pressure reading
Time frame: 1 year
Change in LDLc, HDLc, cholesterol, and triglyceride values
University of Pittsburgh
Other
Redesigning Medication Intensification Effectiveness Study for Diabetes
Acronym: Remedies4D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details